Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 2010;3:233-45. [PMID: 20086181 DOI: 10.1158/1940-6207.capr-09-0108] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]

For:	Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 2010;3:233-45. [PMID: 20086181 DOI: 10.1158/1940-6207.capr-09-0108] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]

Number

Cited by Other Article(s)

Qian H, Gong R, Li Y, Zhu J, Wang L. A genetically informed study reveals modifiable pathways in skin cancer. J Transl Med 2024;22:916. [PMID: 39379979 PMCID: PMC11463105 DOI: 10.1186/s12967-024-05719-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2024] [Accepted: 10/02/2024] [Indexed: 10/10/2024] Open

Green AC, Mundra PA, Grant M, Marais R, Cook MG. Frequency of naevus cells in lymph nodes of melanoma and breast cancer patients. Pathol Res Pract 2024;254:155106. [PMID: 38271783 DOI: 10.1016/j.prp.2024.155106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 12/19/2023] [Accepted: 01/06/2024] [Indexed: 01/27/2024]

Talwar JV, Laub D, Pagadala MS, Castro A, Lewis M, Luebeck GE, Gorman BR, Pan C, Dong FN, Markianos K, Teerlink CC, Lynch J, Hauger R, Pyarajan S, Tsao PS, Morris GP, Salem RM, Thompson WK, Curtius K, Zanetti M, Carter H. Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility. Am J Hum Genet 2023;110:1138-1161. [PMID: 37339630 PMCID: PMC10357503 DOI: 10.1016/j.ajhg.2023.05.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 05/20/2023] [Accepted: 05/22/2023] [Indexed: 06/22/2023] Open

Abstract

Autoimmunity and cancer represent two different aspects of immune dysfunction. Autoimmunity is characterized by breakdowns in immune self-tolerance, while impaired immune surveillance can allow for tumorigenesis. The class I major histocompatibility complex (MHC-I), which displays derivatives of the cellular peptidome for immune surveillance by CD8+ T cells, serves as a common genetic link between these conditions. As melanoma-specific CD8+ T cells have been shown to target melanocyte-specific peptide antigens more often than melanoma-specific antigens, we investigated whether vitiligo- and psoriasis-predisposing MHC-I alleles conferred a melanoma-protective effect. In individuals with cutaneous melanoma from both The Cancer Genome Atlas (n = 451) and an independent validation set (n = 586), MHC-I autoimmune-allele carrier status was significantly associated with a later age of melanoma diagnosis. Furthermore, MHC-I autoimmune-allele carriers were significantly associated with decreased risk of developing melanoma in the Million Veteran Program (OR = 0.962, p = 0.024). Existing melanoma polygenic risk scores (PRSs) did not predict autoimmune-allele carrier status, suggesting these alleles provide orthogonal risk-relevant information. Mechanisms of autoimmune protection were neither associated with improved melanoma-driver mutation association nor improved gene-level conserved antigen presentation relative to common alleles. However, autoimmune alleles showed higher affinity relative to common alleles for particular windows of melanocyte-conserved antigens and loss of heterozygosity of autoimmune alleles caused the greatest reduction in presentation for several conserved antigens across individuals with loss of HLA alleles. Overall, this study presents evidence that MHC-I autoimmune-risk alleles modulate melanoma risk unaccounted for by current PRSs.

Collapse

Affiliation(s)

James V Talwar Department of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA 92093, USA
David Laub Department of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA 92093, USA
Meghana S Pagadala Biomedical Science Program, University of California San Diego, La Jolla, CA 92093, USA
Andrea Castro Department of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA 92093, USA
McKenna Lewis Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA 92093, USA
Georg E Luebeck Public Health Sciences Division, Herbold Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Bryan R Gorman Center for Data and Computational Sciences (C-DACS), VA Boston Healthcare System, Boston, MA 02130, USA; Booz Allen Hamilton, Inc., McLean, VA 22102, USA
Cuiping Pan Palo Alto Epidemiology Research and Information Center for Genomics, VA Palo Alto, CA, USA
Frederick N Dong Center for Data and Computational Sciences (C-DACS), VA Boston Healthcare System, Boston, MA 02130, USA; Booz Allen Hamilton, Inc., McLean, VA 22102, USA
Kyriacos Markianos Center for Data and Computational Sciences (C-DACS), VA Boston Healthcare System, Boston, MA 02130, USA; Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02115, USA
Craig C Teerlink Department of Veterans Affairs Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Healthcare System, Salt Lake City, UT, USA; Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA
Julie Lynch Department of Veterans Affairs Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Healthcare System, Salt Lake City, UT, USA; Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA
Richard Hauger VA San Diego Healthcare System, La Jolla, CA, USA; Center for Behavioral Genetics of Aging, University of California San Diego, La Jolla, CA, USA; Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, CA, USA
Saiju Pyarajan Center for Data and Computational Sciences (C-DACS), VA Boston Healthcare System, Boston, MA 02130, USA; Department of Medicine, Brigham Women's Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA
Philip S Tsao Palo Alto Epidemiology Research and Information Center for Genomics, VA Palo Alto, CA, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
Gerald P Morris Department of Pathology, University of California San Diego, La Jolla, CA 92093, USA
Rany M Salem Division of Epidemiology, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA 92093, USA
Wesley K Thompson Center for Population Neuroscience and Genetics, Laureate Institute for Brain Research, Tulsa, OK 74136, USA
Kit Curtius Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA; Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA
Maurizio Zanetti Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA; The Laboratory of Immunology, University of California San Diego, La Jolla, CA 92093, USA; Department of Medicine, Division of Hematology and Oncology, University of California San Diego, La Jolla, CA 92093, USA
Hannah Carter Department of Medicine, Division of Medical Genetics, University of California San Diego, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.

Collapse

Newell F, Johansson PA, Wilmott JS, Nones K, Lakis V, Pritchard AL, Lo SN, Rawson RV, Kazakoff SH, Colebatch AJ, Koufariotis LT, Ferguson PM, Wood S, Leonard C, Law MH, Brooks KM, Broit N, Palmer JM, Couts KL, Vergara IA, Long GV, Barbour AP, Nieweg OE, Shivalingam B, Robinson WA, Stretch JR, Spillane AJ, Saw RP, Shannon KF, Thompson JF, Mann GJ, Pearson JV, Scolyer RA, Waddell N, Hayward NK. Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes. Cancer Discov 2022;12:2856-2879. [PMID: 36098958 PMCID: PMC9716259 DOI: 10.1158/2159-8290.cd-22-0603] [Citation(s) in RCA: 51] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 08/01/2022] [Accepted: 09/02/2022] [Indexed: 01/12/2023]

Affiliation(s)

Felicity Newell QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.,Corresponding Authors: Felicity Newell, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia. Phone: 61-7-3845-3965; E-mail: ; Richard A. Scolyer, Melanoma Institute Australia, 40 Rockland Road, Wollstonecraft, Sydney, NSW 2065, Australia. Phone: 61-2-9515-7011; E-mail: ; and Nicola Waddell, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia. Phone: 61-7-3845-3538;
Peter A. Johansson QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
James S. Wilmott Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia
Katia Nones QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Vanessa Lakis QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Antonia L. Pritchard QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.,Department of Genetics and Immunology, Division of Biomedical Science, University of the Highlands and Islands, Inverness, Scotland, United Kingdom
Serigne N. Lo Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia
Robert V. Rawson Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia
Stephen H. Kazakoff QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Andrew J. Colebatch Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia
Lambros T. Koufariotis QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Peter M. Ferguson Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia
Scott Wood QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Conrad Leonard QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Matthew H. Law QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.,Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
Kelly M. Brooks QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Natasa Broit QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.,Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.,Q-Gen Cell Therapeutics, Brisbane, Queensland, Australia
Jane M. Palmer QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Kasey L. Couts Center for Rare Melanomas, University of Colorado Cancer Center, Aurora, Colorado
Ismael A. Vergara Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia
Georgina V. Long Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.,Mater Hospital, North Sydney, New South Wales, Australia.,Royal North Shore Hospital, St Leonards, New South Wales, Australia
Andrew P. Barbour Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia
Omgo E. Nieweg Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Brindha Shivalingam Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Mater Hospital, North Sydney, New South Wales, Australia.,Department of Neurosurgery, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.,Department of Neurosurgery, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
William A. Robinson Center for Rare Melanomas, University of Colorado Cancer Center, Aurora, Colorado
Jonathan R. Stretch Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Mater Hospital, North Sydney, New South Wales, Australia.,Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Andrew J. Spillane Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Mater Hospital, North Sydney, New South Wales, Australia.,Royal North Shore Hospital, St Leonards, New South Wales, Australia
Robyn P.M. Saw Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Mater Hospital, North Sydney, New South Wales, Australia.,Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Kerwin F. Shannon Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
John F. Thompson Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Mater Hospital, North Sydney, New South Wales, Australia.,Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Graham J. Mann Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia.,John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
John V. Pearson QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Richard A. Scolyer Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.,Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.,Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.,Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.,Corresponding Authors: Felicity Newell, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia. Phone: 61-7-3845-3965; E-mail: ; Richard A. Scolyer, Melanoma Institute Australia, 40 Rockland Road, Wollstonecraft, Sydney, NSW 2065, Australia. Phone: 61-2-9515-7011; E-mail: ; and Nicola Waddell, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia. Phone: 61-7-3845-3538;
Nicola Waddell QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.,Corresponding Authors: Felicity Newell, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia. Phone: 61-7-3845-3965; E-mail: ; Richard A. Scolyer, Melanoma Institute Australia, 40 Rockland Road, Wollstonecraft, Sydney, NSW 2065, Australia. Phone: 61-2-9515-7011; E-mail: ; and Nicola Waddell, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006, Australia. Phone: 61-7-3845-3538;
Nicholas K. Hayward QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Collapse

Seviiri M, Scolyer RA, Bishop DT, Newton-Bishop JA, Iles MM, Lo SN, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Gordon SD, Olsen CM, Whiteman DC, Landi MT, Thompson JF, Long GV, MacGregor S, Law MH. Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting. J Transl Med 2022;20:403. [PMID: 36064556 PMCID: PMC9446843 DOI: 10.1186/s12967-022-03613-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 08/24/2022] [Indexed: 12/03/2022] Open

Abstract

BACKGROUND

The role of germline genetic factors in determining survival from cutaneous melanoma (CM) is not well understood.

OBJECTIVE

To perform a genome-wide association study (GWAS) meta-analysis of melanoma-specific survival (MSS), and test whether a CM-susceptibility polygenic risk score (PRS) is associated with MSS.

METHODS

We conducted two Cox proportional-hazard GWAS of MSS using data from the Melanoma Institute Australia, a high ultraviolet (UV) radiation setting (MIA; 5,762 patients with melanoma; 800 melanoma deaths) and UK Biobank (UKB: 5,220 patients with melanoma; 241 melanoma deaths), and combined them in a fixed-effects meta-analysis. Significant (P < 5 × 10-8) results were investigated in the Leeds Melanoma Cohort (LMC; 1,947 patients with melanoma; 370 melanoma deaths). We also developed a CM-susceptibility PRS using a large independent GWAS meta-analysis (23,913 cases, 342,870 controls). The PRS was tested for an association with MSS in the MIA and UKB cohorts.

RESULTS

Two loci were significantly associated with MSS in the meta-analysis of MIA and UKB with lead SNPs rs41309643 (G allele frequency 1.6%, HR = 2.09, 95%CI = 1.61-2.71, P = 2.08 × 10-8) on chromosome 1, and rs75682113 (C allele frequency 1.8%, HR = 2.38, 95%CI = 1.77-3.21, P = 1.07 × 10-8) on chromosome 7. While neither SNP replicated in the LMC, rs75682113 was significantly associated in the combined discovery and replication sets. After adjusting for age at diagnosis, sex and the first ten principal components, a one standard deviation increase in the CM-susceptibility PRS was associated with improved MSS in the discovery meta-analysis (HR = 0.88, 95% CI = 0.83-0.94, P = 6.93 × 10-5; I2 = 88%). However, this was only driven by the high UV setting cohort (MIA HR = 0.84, 95% CI = 0.78-0.90).

CONCLUSION

We found two loci potentially associated with MSS. Increased genetic susceptibility to develop CM is associated with improved MSS in a high UV setting.

Collapse

Affiliation(s)

Mathias Seviiri Statistical Genetics Lab, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006 Australia School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD Australia Center for Genomics and Personalised Health, Queensland University of Technology, Brisbane, QLD Australia
Richard A. Scolyer Melanoma Institute Australia, The University of Sydney, Sydney, NSW Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW Australia Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital, Sydney, NSW Australia NSW Health Pathology, Sydney, NSW Australia
D. Timothy Bishop Division of Haematology and Immunology, Leeds Institute of Medical Research at St James’, University of Leeds, Leeds, UK
Julia A. Newton-Bishop Division of Haematology and Immunology, Leeds Institute of Medical Research at St James’, University of Leeds, Leeds, UK
Mark M. Iles St James’s Institute of Medical Research, University of Leeds, Leeds, UK Leeds Institute of Data Analytics, University of Leeds, Leeds, UK
Serigne N. Lo Melanoma Institute Australia, The University of Sydney, Sydney, NSW Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW Australia
Johnathan R. Stretch Melanoma Institute Australia, The University of Sydney, Sydney, NSW Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW Australia Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW Australia
Robyn P. M. Saw Melanoma Institute Australia, The University of Sydney, Sydney, NSW Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW Australia Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW Australia
Omgo E. Nieweg Melanoma Institute Australia, The University of Sydney, Sydney, NSW Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW Australia Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW Australia
Kerwin F. Shannon Melanoma Institute Australia, The University of Sydney, Sydney, NSW Australia Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW Australia Sydney Head & Neck Cancer Institute, Chris O’Brien Lifehouse Cancer Center, Sydney, NSW Australia
Andrew J. Spillane Melanoma Institute Australia, The University of Sydney, Sydney, NSW Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW Australia Department of Breast and Melanoma Surgery, Royal North Shore Hospital, Sydney, NSW Australia
Scott D. Gordon Genetic Epidemiology Lab, QIMR Berghofer Medical Research Institute, Brisbane, QLD Australia
Catherine M. Olsen Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD Australia Faculty of Medicine, University of Queensland, Brisbane, QLD Australia
David C. Whiteman Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD Australia
Maria Teresa Landi Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD USA
John F. Thompson Melanoma Institute Australia, The University of Sydney, Sydney, NSW Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW Australia Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW Australia
Georgina V. Long Melanoma Institute Australia, The University of Sydney, Sydney, NSW Australia Faculty of Medicine and Health, The University of Sydney, Sydney, NSW Australia Department of Medical Oncology, Mater Hospital, North Sydney, NSW Australia Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW Australia
Stuart MacGregor Statistical Genetics Lab, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006 Australia School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD Australia
Matthew H. Law Statistical Genetics Lab, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD 4006 Australia School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD Australia

Collapse

Koumaki D, Papadakis M, Kouloumvakou S, Krasagakis K. Awareness, knowledge, and attitudes towards sun protection among patients with melanoma and atypical mole syndrome. World J Clin Oncol 2022;13:587-598. [PMID: 36157160 PMCID: PMC9346423 DOI: 10.5306/wjco.v13.i7.587] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2022] [Revised: 03/18/2022] [Accepted: 06/22/2022] [Indexed: 02/06/2023] Open

Steinberg J, Iles MM, Lee JY, Wang X, Law MH, Smit AK, Nguyen‐Dumont T, Giles GG, Southey MC, Milne RL, Mann GJ, Bishop DT, MacInnis RJ, Cust AE. Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts. Br J Dermatol 2022;186:823-834. [PMID: 34921685 PMCID: PMC9545863 DOI: 10.1111/bjd.20956] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Revised: 11/11/2021] [Accepted: 12/11/2021] [Indexed: 12/05/2022]

Abstract

BACKGROUND

Previous studies suggest that polygenic risk scores (PRSs) may improve melanoma risk stratification. However, there has been limited independent validation of PRS-based risk prediction, particularly assessment of calibration (comparing predicted to observed risks).

OBJECTIVES

To evaluate PRS-based melanoma risk prediction in prospective UK and Australian cohorts with European ancestry.

METHODS

We analysed invasive melanoma incidence in the UK Biobank (UKB; n = 395 647, 1651 cases) and a case-cohort nested within the Melbourne Collaborative Cohort Study (MCCS, Australia; n = 4765, 303 cases). Three PRSs were evaluated: 68 single-nucleotide polymorphisms (SNPs) at 54 loci from a 2020 meta-analysis (PRS68), 50 SNPs significant in the 2020 meta-analysis excluding UKB (PRS50) and 45 SNPs at 21 loci known in 2018 (PRS45). Ten-year melanoma risks were calculated from population-level cancer registry data by age group and sex, with and without PRS adjustment.

RESULTS

Predicted absolute melanoma risks based on age and sex alone underestimated melanoma incidence in the UKB [ratio of expected/observed cases: E/O = 0·65, 95% confidence interval (CI) 0·62-0·68] and MCCS (E/O = 0·63, 95% CI 0·56-0·72). For UKB, calibration was improved by PRS adjustment, with PRS50-adjusted risks E/O = 0·91, 95% CI 0·87-0·95. The discriminative ability for PRS68- and PRS50-adjusted absolute risks was higher than for risks based on age and sex alone (Δ area under the curve 0·07-0·10, P < 0·0001), and higher than for PRS45-adjusted risks (Δ area under the curve 0·02-0·04, P < 0·001).

CONCLUSIONS

A PRS derived from a larger, more diverse meta-analysis improves risk prediction compared with an earlier PRS, and might help tailor melanoma prevention and early detection strategies to different risk levels. Recalibration of absolute risks may be necessary for application to specific populations.

Collapse

Affiliation(s)

Julia Steinberg The Daffodil CentreThe University of Sydney, a joint venture with Cancer Council NSWSydneyNSWAustralia
Mark M. Iles Leeds Institute for Data AnalyticsUniversity of LeedsLeedsUK
Jin Yee Lee School of Public HealthThe University of SydneySydneyNSWAustralia
Xiaochuan Wang Cancer Epidemiology DivisionCancer Council VictoriaMelbourneVICAustralia
Matthew H. Law Statistical Genetics LaboratoryQIMR Berghofer Medical Research InstituteBrisbaneQLDAustralia School of Biomedical Sciences, Faculty of Health, and Institute of Health and Biomedical InnovationQueensland University of TechnologyKelvin GroveQLDAustralia
Amelia K. Smit The Daffodil CentreThe University of Sydney, a joint venture with Cancer Council NSWSydneyNSWAustralia
Tu Nguyen‐Dumont Precision Medicine, School of Clinical Sciences at Monash HealthMonash UniversityClaytonVICAustralia Department of Clinical PathologyThe University of MelbourneMelbourneVICAustralia
Graham G. Giles Cancer Epidemiology DivisionCancer Council VictoriaMelbourneVICAustralia Precision Medicine, School of Clinical Sciences at Monash HealthMonash UniversityClaytonVICAustralia Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global HealthThe University of MelbourneMelbourneVICAustralia
Melissa C. Southey Precision Medicine, School of Clinical Sciences at Monash HealthMonash UniversityClaytonVICAustralia
Roger L. Milne Cancer Epidemiology DivisionCancer Council VictoriaMelbourneVICAustralia Precision Medicine, School of Clinical Sciences at Monash HealthMonash UniversityClaytonVICAustralia Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global HealthThe University of MelbourneMelbourneVICAustralia
Graham J. Mann John Curtin School of Medical ResearchAustralian National UniversityCanberraACTAustralia
D. Timothy Bishop Leeds Institute for Data AnalyticsUniversity of LeedsLeedsUK
Robert J. MacInnis Cancer Epidemiology DivisionCancer Council VictoriaMelbourneVICAustralia Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global HealthThe University of MelbourneMelbourneVICAustralia
Anne E. Cust The Daffodil CentreThe University of Sydney, a joint venture with Cancer Council NSWSydneyNSWAustralia Melanoma Institute AustraliaThe University of SydneySydneyNSWAustralia

Collapse

Perez M, Abisaad JA, Rojas KD, Marchetti MA, Jaimes N. Skin Cancer: Primary, Secondary, and Tertiary Prevention. Part I. J Am Acad Dermatol 2022;87:255-268. [DOI: 10.1016/j.jaad.2021.12.066] [Citation(s) in RCA: 60] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 12/03/2021] [Accepted: 12/15/2021] [Indexed: 10/19/2022]

Kyprianou D, Charalambidou I, Famojuro O, Wang H, Su D, Farazi PA. Knowledge and Attitudes of Cypriots on Melanoma Prevention: Is there a Public Health Concern? BMC Public Health 2022;22:53. [PMID: 34998365 PMCID: PMC8742933 DOI: 10.1186/s12889-021-12324-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Accepted: 11/28/2021] [Indexed: 11/11/2022] Open

Abstract

Background

Melanoma is the deadliest type of skin cancer. It is the eighth most common cancer in males and the tenth in females in Cyprus, an island in the Mediterranean with a high ultraviolet (UV) index. Cyprus is expected to be strongly affected by climate change and consequently, melanoma will likely become an increasing public health problem. Melanoma prevention is possible; however, it is unknown if people living in Cyprus are aware of melanoma and prevention methods. To this end, we used a validated survey to evaluate the level of melanoma knowledge and factors associated with it in the Cypriot population.

Methods

We conducted a 47-item survey with sections on demographics, knowledge of melanoma and risk factors, attitudes toward relevant health practices, and protective behaviors among six hundred Cypriot residents from October 2015 to April 2016.

Results

Our results revealed that only 59% of participants check their skin for moles, 87% protect their skin from the sun during summer holidays, and 57% do not take measures to protect their skin from the sun during non-holiday periods. Protective behavior was positively associated with educational level (P=0.016) and district of residence (P<0.0001). Melanoma knowledge was positively associated with education level (P=0.002) and district of residence (P=0.004). Level of Concern was positively associated with age (P=0.026) and education level (P=0.041).

Conclusions

There are gaps in melanoma knowledge and prevention practices in the study population. Further education on melanoma and its prevention should be specifically targeted to individuals of lower education levels as well as teenagers, such that protective behaviors for melanoma are adopted early in life.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12889-021-12324-0.

Collapse

Borden ES, Adams AC, Buetow KH, Wilson MA, Bauman JE, Curiel-Lewandrowski C, Chow HHS, LaFleur BJ, Hastings KT. Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma. Cancers (Basel) 2021;14:cancers14010003. [PMID: 35008167 PMCID: PMC8749980 DOI: 10.3390/cancers14010003] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 12/16/2021] [Accepted: 12/20/2021] [Indexed: 02/07/2023] Open

Abstract

Simple Summary

Melanoma is a deadly skin cancer, and the incidence of melanoma is rising. Chemoprevention, using small molecule drugs to prevent the development of cancer, is a key strategy that could reduce the burden of melanoma on society. The long-term goal of our study is to develop a gene signature biomarker of progression from nevi to melanoma. We found that a small number of genes can distinguish nevi from melanoma and identified shared genes and immune-related pathways that are associated with progression from nevi to melanoma across independent datasets. This study demonstrates (1) a novel approach to aid melanoma chemoprevention trials by using a gene signature as a surrogate endpoint and (2) the feasibility of determining a gene signature biomarker of melanoma progression.

Abstract

There is a need to identify molecular biomarkers of melanoma progression to assist the development of chemoprevention strategies to lower melanoma incidence. Using datasets containing gene expression for dysplastic nevi and melanoma or melanoma arising in a nevus, we performed differential gene expression analysis and regularized regression models to identify genes and pathways that were associated with progression from nevi to melanoma. A small number of genes distinguished nevi from melanoma. Differential expression of seven genes was identified between nevi and melanoma in three independent datasets. C1QB, CXCL9, CXCL10, DFNA5 (GSDME), FCGR1B, and PRAME were increased in melanoma, and SCGB1D2 was decreased in melanoma, compared to dysplastic nevi or nevi that progressed to melanoma. Further supporting an association with melanomagenesis, these genes demonstrated a linear change in expression from benign nevi to dysplastic nevi to radial growth phase melanoma to vertical growth phase melanoma. The genes associated with melanoma progression showed significant enrichment of multiple pathways related to the immune system. This study demonstrates (1) a novel application of bioinformatic approaches to aid clinical trials of melanoma chemoprevention and (2) the feasibility of determining a gene signature biomarker of melanomagenesis.

Collapse

Affiliation(s)

Elizabeth S. Borden Department of Basic Medical Sciences, University of Arizona College of Medicine Phoenix, Phoenix, AZ 85004, USA; (E.S.B.); (A.C.A.) Phoenix Veterans Affairs Health Care System, Phoenix, AZ 85012, USA
Anngela C. Adams Department of Basic Medical Sciences, University of Arizona College of Medicine Phoenix, Phoenix, AZ 85004, USA; (E.S.B.); (A.C.A.) Phoenix Veterans Affairs Health Care System, Phoenix, AZ 85012, USA
Kenneth H. Buetow School of Life Sciences, Arizona State University, Tempe, AZ 85281, USA; (K.H.B.); (M.A.W.) Center for Evolution and Medicine, Arizona State University, Tempe, AZ 85281, USA
Melissa A. Wilson School of Life Sciences, Arizona State University, Tempe, AZ 85281, USA; (K.H.B.); (M.A.W.) Center for Evolution and Medicine, Arizona State University, Tempe, AZ 85281, USA
Julie E. Bauman Department of Medicine, University of Arizona College of Medicine Tucson, Tucson, AZ 85724, USA; (J.E.B.); (C.C.-L.); (H.-H.S.C.) University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
Clara Curiel-Lewandrowski Department of Medicine, University of Arizona College of Medicine Tucson, Tucson, AZ 85724, USA; (J.E.B.); (C.C.-L.); (H.-H.S.C.) University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
H.-H. Sherry Chow Department of Medicine, University of Arizona College of Medicine Tucson, Tucson, AZ 85724, USA; (J.E.B.); (C.C.-L.); (H.-H.S.C.) University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
Bonnie J. LaFleur BIO5 Institute, University of Arizona, Tucson, AZ 85724, USA;
Karen Taraszka Hastings Department of Basic Medical Sciences, University of Arizona College of Medicine Phoenix, Phoenix, AZ 85004, USA; (E.S.B.); (A.C.A.) Phoenix Veterans Affairs Health Care System, Phoenix, AZ 85012, USA University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA Correspondence: ; Tel.: +1-602-827-2106

Collapse

Zhang KS, Pelleg T, Campbell S, Rubio C, Loschner AL, Ie S. Pulmonary metastatic melanoma: current state of diagnostic imaging and treatments. Melanoma Manag 2021;8:MMT58. [PMID: 34900220 PMCID: PMC8656320 DOI: 10.2217/mmt-2021-0001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Accepted: 06/16/2021] [Indexed: 12/13/2022] Open

Dusingize JC, Law MH, Pandeya N, Neale RE, Ong JS, MacGregor S, Whiteman DC, Olsen CM. Genetically determined cutaneous nevi and risk of cancer. Int J Cancer 2021;150:961-968. [PMID: 34778946 DOI: 10.1002/ijc.33874] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 10/14/2021] [Accepted: 10/22/2021] [Indexed: 01/07/2023]

Iacullo J, Barriera-Silvestrini P, Knackstedt TJ. Dermatologic Follow-up and Assessment of Suspicious Lesions. Clin Plast Surg 2021;48:617-629. [PMID: 34503722 DOI: 10.1016/j.cps.2021.05.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]

Laskar R, Ferreiro-Iglesias A, Bishop DT, Iles MM, Kanetsky PA, Armstrong BK, Law MH, Goldstein AM, Aitken JF, Giles GG, Australian Melanoma Family Study Investigators, Leeds Case-Control Study Investigators, Hilary A Robbins, Cust AE. Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity. Br J Dermatol 2021;184:1085-1093. [PMID: 33270213 PMCID: PMC9969114 DOI: 10.1111/bjd.19705] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/30/2020] [Indexed: 12/15/2022]

Affiliation(s)

Ruhina Laskar International Agency for Research on Cancer, Lyon, France
Aida Ferreiro-Iglesias International Agency for Research on Cancer, Lyon, France
D Timothy Bishop Leeds Institute of Haematology and Immunology, University of Leeds, Leeds, UK
Mark M Iles Division of Haematology and Immunology, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, UK Leeds Institute of Data Analytics, University of Leeds, Leeds, UK
Peter A Kanetsky Cancer Epidemiology Program, Moffitt Cancer Center, Tampa, FL, USA
Bruce K Armstrong Cancer Epidemiology and Prevention Research Group, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
Matthew H Law Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia Queensland University of Technology (QUT), Brisbane, Australia
Alisa M Goldstein Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
Joanne F Aitken Viertel Centre for Research in Cancer Control, the Cancer Council Queensland, Brisbane, Australia
Graham G Giles Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, Victoria 3004, Australia Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
Australian Melanoma Family Study Investigators
Leeds Case-Control Study Investigators
Hilary A Robbins International Agency for Research on Cancer, Lyon, France
Anne E Cust International Agency for Research on Cancer, Lyon, France Cancer Epidemiology and Prevention Research Group, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia The Melanoma Institute Australia, The University of Sydney, Sydney, Australia

Collapse

Serra F, Barruscotti S, Dominioni T, Zuccarini A, Pedrazzoli P, Chiellino S. Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need. Curr Oncol Rep 2021;23:84. [PMID: 34009481 DOI: 10.1007/s11912-021-01065-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/30/2021] [Indexed: 12/28/2022]

Abstract

INTRODUCTION

In the last few years, the advent of targeted therapy and immunotherapy has improved the management and the prognosis of metastatic melanoma, but the spread of resistance mechanisms can lead to disease progression. The clinical management in this setting can be challenging because the oncologist has to decide what is the best treatment strategy among therapy beyond progression (TBP), therapy change, and the rechallenge approach. This review of the relevant scientific literature is intended to clarify which patients with progressing metastatic melanoma will benefit from continuation of ongoing therapy and which ones will not. The data are based on a total of about 4300 patients coming from the main retrospective studies in the chosen field. The article body is divided into four sections which analyze respectively the targeted therapy beyond progression, the immunotherapy beyond progression, the possible treatment sequences, and finally the rechallenge strategy.

RECENT FINDINGS

Despite the possible approaches of TBP or rechallenge, the patient may not have an optimal response and may need new therapy, which is currently missing. To broaden the pharmacological offer in the fight against melanoma, cancer research is studying new disease targets, like the NRAS, PI3K, and cKIT pathways or combination treatment of targeted therapy plus immunotherapy. Despite the limitations of this work, mainly due to the limited number of studies, their retrospective nature and the lack of comparative studies, the analysis performed allows us to draw some important conclusions: therapy beyond progression, both targeted therapy and immunotherapy, represents a valid treatment option with positive effects on disease control and survival outcomes for patients with low clinical risk, expressed as low disease burden, normal LDH levels, and good performance status; moreover, the prognosis and quality of life of these patients improve when TBP is associated with locoregional treatments. In patients with progressive metastatic melanoma and high clinical risk (high disease burden, high LDH levels, and poor performance status), it is recommended to change therapy, without ever forgetting the possibility of enrolling the patient in a clinical trial. Finally, an efficacious treatment alternative is the rechallenge strategy; this approach consists in a re-treatment with the same drug after a variable interval of discontinuation. Preliminary studies seem to have demonstrated that patients retreated with targeted therapy achieved a greater benefit if they had a low clinical risk and if the drug doublet (BRAF + MEK inhibitors) was used. On the side of immunotherapy, the rechallenge strategy produced a major benefit in patients who prior experienced a severe toxic episode.

Collapse

School-based interventions to improve sun-safe knowledge, attitudes and behaviors in childhood and adolescence: A systematic review. Prev Med 2021;146:106459. [PMID: 33609617 DOI: 10.1016/j.ypmed.2021.106459] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2020] [Revised: 02/06/2021] [Accepted: 02/08/2021] [Indexed: 11/23/2022]

Abstract

Ultraviolet radiation exposure is the leading cause of skin cancer, and childhood and adolescence is a particularly susceptible life period for exposure. This systematic review assessed whether interventions in elementary and secondary school settings reduced sun exposure, sunburns, and development of melanocytic nevi, and improved sun-safe knowledge, attitudes and sun protection behaviors in childhood and adolescence. A systematic search up to June 2020 of MEDLINE, Embase, CINAHL, Cochrane and ProQuest databases was undertaken, for studies conducted among students in an elementary or secondary school setting that compared an intervention group with a pre-intervention or separate control group. Data were summarized using qualitative synthesis. Pooled effects from meta-analysis with random effects were also reported where appropriate. Sixty-five studies were included (22 randomized, 43 non-randomized). Most studies assessed measures of sun-safe behaviors, knowledge and attitudes (57, 48 and 33 studies, respectively), and observed improved sun protection behaviors and sun-safe knowledge, whereas few studies reduced time in the sun. About half improved participants' attitudes towards tanning desirability. Sunburns and nevus counts were less frequently assessed, but about half of these studies observed a reduction. There was substantial heterogeneity for outcomes except attitudes towards the desirability of tanning (pooled odds ratio from 6 studies: 0.81, 95% confidence interval 0.70-0.94). Key positive intervention features included: elementary school settings, interactive features or multiple components, and incorporating social norm influences. Most studies were classified at high risk of bias. In conclusion, school-based sun-related interventions had positive impacts on behaviors and attitudes among elementary and secondary school children.

Collapse

Cust A. A different finding on whether naevus numbers change during adulthood. Br J Dermatol 2020;184:193. [DOI: 10.1111/bjd.19619] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Accepted: 10/06/2020] [Indexed: 02/05/2023]

Orthopaedic Manifestations of Melanoma and Their Management. J Am Acad Orthop Surg 2020;28:e540-e549. [PMID: 32097135 DOI: 10.5435/jaaos-d-18-00757] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open

Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, Mandala M, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Dębniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hočevar M, Höiom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubiński J, Mackie RM, Malt M, Malvehy J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novaković S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butille JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, et alLandi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, Mandala M, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Dębniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hočevar M, Höiom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubiński J, Mackie RM, Malt M, Malvehy J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novaković S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butille JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, Schulze HJ, Simms LA, Smithers M, Song F, Swerdlow AJ, van der Stoep N, Kukutsch NA, Visconti A, Wallace L, Ward SV, Wheeler L, Sturm RA, Hutchinson A, Jones K, Malasky M, Vogt A, Zhou W, Pooley KA, Elder DE, Han J, Hicks B, Hayward NK, Kanetsky PA, Brummett C, Montgomery GW, Olsen CM, Hayward C, Dunning AM, Martin NG, Evangelou E, Mann GJ, Long G, Pharoah PDP, Easton DF, Barrett JH, Cust AE, Abecasis G, Duffy DL, Whiteman DC, Gogas H, De Nicolo A, Tucker MA, Newton-Bishop JA, Peris K, Chanock SJ, Demenais F, Brown KM, Puig S, Nagore E, Shi J, Iles MM, Law MH. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nat Genet 2020;52:494-504. [PMID: 32341527 PMCID: PMC7255059 DOI: 10.1038/s41588-020-0611-8] [Show More Authors] [Citation(s) in RCA: 153] [Impact Index Per Article: 30.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Accepted: 03/09/2020] [Indexed: 12/17/2022]

Affiliation(s)

Maria Teresa Landi Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
D Timothy Bishop Leeds Institute of Medical Research at St James's, Leeds Institute for Data Analytics, University of Leeds, Leeds, UK
Stuart MacGregor Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Mitchell J Machiela Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Alexander J Stratigos Department of Dermatology, Andreas Syggros Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Paola Ghiorzo Genetics of Rare Cancers, Ospedale Policlinico San Martino, Genoa, Italy Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy
Myriam Brossard Genetic Epidemiology and Functional Genomics of Multifactorial Diseases Team, Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-1124, Université Paris Descartes, Paris, France
Donato Calista Department of Dermatology, Maurizio Bufalini Hospital, Cesena, Italy
Jiyeon Choi Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Maria Concetta Fargnoli Department of Dermatology & Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
Tongwu Zhang Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Monica Rodolfo Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
Adam J Trower Leeds Institute for Data Analytics, University of Leeds, Leeds, UK
Chiara Menin Immunology and Molecular Oncology Unit, Venito Institute of Oncology IOV-IRCCS, Padua, Italy
Jacobo Martinez Red Valenciana de Biobancos, FISABIO, Valencia, Spain
Andreas Hadjisavvas Department of EM/Molecular Pathology & The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
Lei Song Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Irene Stefanaki Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece
Richard Scolyer Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia Royal Prince Alfred Hospital, Sydney, New South Wales, Australia Central Clinical School, The University of Sydney, Sydney, New South Wales, Australia New South Wales Health Pathology, Sydney, New South Wales, Australia
Rose Yang Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Alisa M Goldstein Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Miriam Potrony Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERER, Barcelona, Spain
Katerina P Kypreou Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece
Lorenza Pastorino Genetics of Rare Cancers, Ospedale Policlinico San Martino, Genoa, Italy Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy
Paola Queirolo Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Cristina Pellegrini Department of Dermatology & Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
Laura Cattaneo Pathology Unit, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
Matthew Zawistowski Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI, USA
Pol Gimenez-Xavier Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERER, Barcelona, Spain
Arantxa Rodriguez Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
Lisa Elefanti Immunology and Molecular Oncology Unit, Venito Institute of Oncology IOV-IRCCS, Padua, Italy
Siranoush Manoukian Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
Licia Rivoltini Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
Blair H Smith Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Maria A Loizidou Department of EM/Molecular Pathology & The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
Laura Del Regno Institute of Dermatology, Catholic University, Rome, Italy Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
Daniela Massi Section of Anatomic Pathology, Department of Health Sciences, University of Florence, Florence, Italy
Mario Mandala Department of Oncology, Giovanni XXIII Hospital, Bergamo, Italy
Kiarash Khosrotehrani UQ Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
Lars A Akslen Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway Department of Pathology, Haukeland University Hospital, Bergen, Norway
Christopher I Amos Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
Per A Andresen Department of Pathology, Molecular Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Marie-Françoise Avril Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Service de Dermatologie, Université Paris Descartes, Paris, France
Esther Azizi Department of Dermatology, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv, Israel Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
H Peter Soyer Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
Veronique Bataille Department of Twin Research and Genetic Epidemiology, King's College London, London, UK Department of Dermatology, West Herts NHS Trust, Herts, UK
Bruna Dalmasso Genetics of Rare Cancers, Ospedale Policlinico San Martino, Genoa, Italy Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy
Lisa M Bowdler Sample Processing, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Kathryn P Burdon Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia
Wei V Chen Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Veryan Codd Department of Cardiovascular Sciences, University of Leicester, Leicester, UK NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK
Jamie E Craig Department of Ophthalmology, Flinders University, Adelaide, South Australia, Australia
Tadeusz Dębniak Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Mario Falchi Department of Twin Research and Genetic Epidemiology, King's College London, London, UK Department of Dermatology, West Herts NHS Trust, Herts, UK
Shenying Fang Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Eitan Friedman Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Sarah Simi Section of Anatomic Pathology, Department of Health Sciences, University of Florence, Florence, Italy
Pilar Galan Université Paris 13, Equipe de Recherche en Epidémiologie Nutritionnelle (EREN), Centre de Recherche en Epidémiologie et Statistiques, Institut National de la Santé et de la Recherche Médicale (INSERM U1153), Institut National de la Recherche Agronomique (INRA U1125), Conservatoire National des Arts et Métiers, Communauté d'Université Sorbonne Paris Cité, Bobigny, France
Zaida Garcia-Casado Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
Elizabeth M Gillanders Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore, MD, USA
Scott Gordon Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Adele Green Cancer and Population Studies, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia CRUK Manchester Institute, Institute of Inflammation and Repair, University of Manchester, Manchester, UK
Nelleke A Gruis Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands
Johan Hansson Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Mark Harland Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
Jessica Harris Translational Research Institute, Institute of Health and Biomedical Innovation, Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Queensland, Australia
Per Helsing Department of Dermatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Anjali Henders Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
Marko Hočevar Department of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
Veronica Höiom Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
David Hunter Nuffield Department of Population Health, University of Oxford, Oxford, UK Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Christian Ingvar Department of Surgery, Clinical Sciences, Lund University, Lund, Sweden
Rajiv Kumar Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany
Julie Lang Department of Medical Genetics, University of Glasgow, Glasgow, UK
G Mark Lathrop McGill University and Genome Quebec Innovation Centre, Montreal, Canada
Jeffrey E Lee Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Xin Li Department of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA
Jan Lubiński International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
Rona M Mackie Department of Medical Genetics, University of Glasgow, Glasgow, UK Department of Public Health, University of Glasgow, Glasgow, UK
Maryrose Malt Cancer and Population Studies, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Josep Malvehy Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERER, Barcelona, Spain
Kerrie McAloney Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Hamida Mohamdi Genetic Epidemiology and Functional Genomics of Multifactorial Diseases Team, Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-1124, Université Paris Descartes, Paris, France
Anders Molven Department of Pathology, Haukeland University Hospital, Bergen, Norway Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Eric K Moses Centre for Genetic Origins of Health and Disease, Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Crawley, Western Australia, Australia
Rachel E Neale Cancer Aetiology & Prevention, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Srdjan Novaković Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia
Dale R Nyholt Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia School of Biomedical Sciences and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia
Håkan Olsson Department of Oncology/Pathology, Clinical Sciences, Lund University, Lund, Sweden Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden
Nicholas Orr Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
Lars G Fritsche Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
Joan Anton Puig-Butille Biochemistry and Molecular Genetics Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona,CIBERER, Barcelona, Spain
Abrar A Qureshi Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, RI, USA
Graham L Radford-Smith Inflammatory Bowel Diseases, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia Department of Gastroenterology and Hepatology, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia University of Queensland School of Medicine, Herston Campus, Brisbane, Queensland, Australia
Juliette Randerson-Moor Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
Celia Requena Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
Casey Rowe UQ Diamantina Institute, The University of Queensland, Brisbane, Queensland, Australia
Nilesh J Samani Department of Cardiovascular Sciences, University of Leicester, Leicester, UK NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK
Marianna Sanna Department of Twin Research and Genetic Epidemiology, King's College London, London, UK Department of Dermatology, West Herts NHS Trust, Herts, UK
Dirk Schadendorf Department of Dermatology, University Hospital Essen, Essen, Germany German Consortium Translational Cancer Research (DKTK), Heidelberg, Germany
Hans-Joachim Schulze Department of Dermatology, Fachklinik Hornheide, Institute for Tumors of the Skin, University of Münster, Münster, Germany
Lisa A Simms Inflammatory Bowel Diseases, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Mark Smithers Queensland Melanoma Project, Princess Alexandra Hospital, The University of Queensland, St Lucia, Queensland, Australia Mater Research Institute, The University of Queensland, St Lucia, Queensland, Australia
Fengju Song Departments of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P. R. China
Anthony J Swerdlow Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK Division of Breast Cancer Research, The Institute of Cancer Research, London, UK
Nienke van der Stoep Department of Clinical Genetics, Center of Human and Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands
Nicole A Kukutsch Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands
Alessia Visconti Department of Twin Research and Genetic Epidemiology, King's College London, London, UK Department of Dermatology, West Herts NHS Trust, Herts, UK
Leanne Wallace Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
Sarah V Ward Centre for Genetic Origins of Health and Disease, School of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Lawrie Wheeler Translational Research Institute, Institute of Health and Biomedical Innovation, Princess Alexandra Hospital, Queensland University of Technology, Brisbane, Queensland, Australia
Richard A Sturm Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
Amy Hutchinson Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA
Kristine Jones Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA
Michael Malasky Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA
Aurelie Vogt Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA
Weiyin Zhou Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA
Karen A Pooley Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
David E Elder Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Jiali Han Department of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA
Belynda Hicks Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Cancer Genome Research Laboratory, Leidos Biomedical Research, Bethesda, MD, USA
Nicholas K Hayward Oncogenomics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Peter A Kanetsky Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Chad Brummett Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA
Grant W Montgomery Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia
Catherine M Olsen Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Caroline Hayward MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK
Alison M Dunning Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
Nicholas G Martin Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Evangelos Evangelou Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece Department of Epidemiology and Biostatistics, Imperial College London, London, UK
Graham J Mann Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, Australia John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia
Georgina Long Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia Royal North Shore Hospital, Sydney, Australia
Paul D P Pharoah Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
Douglas F Easton Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
Jennifer H Barrett Leeds Institute for Data Analytics, University of Leeds, Leeds, UK
Anne E Cust Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia Cancer Epidemiology and Prevention Research, Sydney School of Public Health, Sydney, Australia
Goncalo Abecasis Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
David L Duffy Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
David C Whiteman Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
Helen Gogas First Department of Internal Medicine, Laikon General Hospital Greece, National and Kapodistrian University of Athens, Athens, Greece
Arcangela De Nicolo Cancer Genomics Program, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Margaret A Tucker Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Julia A Newton-Bishop Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK
Ketty Peris Institute of Dermatology, Catholic University, Rome, Italy Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
Stephen J Chanock Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Florence Demenais Genetic Epidemiology and Functional Genomics of Multifactorial Diseases Team, Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-1124, Université Paris Descartes, Paris, France
Kevin M Brown Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Susana Puig Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, CIBERER, Barcelona, Spain
Eduardo Nagore Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
Jianxin Shi Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Mark M Iles Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
Matthew H Law Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Collapse

Murakami K, Tobino K, Yamaji Y, Ooi R, Munechika M, Enzan Y, Yoshimatsu Y, Tsuruno K, Ide H, Ebi N. Primary Pleural Melanoma: A Case Report and Literature Review. Intern Med 2019;58:3273-3276. [PMID: 31327838 PMCID: PMC6911739 DOI: 10.2169/internalmedicine.3111-19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open

Germano A, Cardili L, Carapeto FCL, Landman G. BRAFV600E and KIT immunoexpression in early-stage melanoma. An Bras Dermatol 2019;94:458-460. [PMID: 31644622 PMCID: PMC7007021 DOI: 10.1590/abd1806-4841.20198349] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Accepted: 06/27/2018] [Indexed: 02/03/2023] Open

Cust A, Drummond M, Bishop D, Azizi L, Schmid H, Jenkins M, Hopper J, Armstrong B, Aitken J, Kefford R, Giles G, Demenais F, Goldstein A, Barrett J, Kanetsky P, Elder D, Mann G, Newton‐Bishop J. Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure. J Eur Acad Dermatol Venereol 2019;33:1874-1885. [PMID: 31087403 PMCID: PMC6800761 DOI: 10.1111/jdv.15680] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Accepted: 05/03/2019] [Indexed: 11/29/2022]

Abstract

BACKGROUND

People at high risk of developing melanoma are usually identified by pigmentary and naevus phenotypes.

OBJECTIVE

We examined whether associations of these phenotypes with melanoma risk differed by ambient sun exposure or participant characteristics in two population-based, case-control studies with comparable ancestry but different ambient sun exposure.

METHODS

Data were analysed from 616 cases and 496 controls from the Australian Melanoma Family Study and 2012 cases and 504 controls from the Leeds (UK) case-control study. Questionnaire, interview and dermatological skin examination data were collected using the same measurement protocols. Relative risks were estimated as odds ratios using unconditional logistic regression, adjusted for potential confounders.

RESULTS

Hair and skin colour were the strongest pigmentary phenotype risk factors. All associations of pigmentary phenotype with melanoma risk were similar across countries. The median number of clinically assessed naevi was approximately three times higher in Australia than Leeds, but the relative risks for melanoma associated with each additional common or dysplastic naevus were higher for Leeds than Australia, especially for naevi on the upper and lower limbs. Higher naevus counts on the head and neck were associated with a stronger relative risk for melanoma for women than men. The two countries had similar relative risks for melanoma based on self-reported naevus density categories, but personal perceptions of naevus number differed by country. There was no consistent evidence of interactions between phenotypes on risk.

CONCLUSIONS

Classifying people at high risk of melanoma based on their number of naevi should ideally take into account their country of residence, type of counts (clinical or self-reported), body site on which the naevus counts are measured and sex. The presence of naevi may be a stronger indicator of a genetic predisposition in the UK than in Australia based on less opportunity for sun exposure to influence naevus development.

Collapse

Affiliation(s)

A.E. Cust Cancer Epidemiology and Prevention ResearchSydney School of Public HealthThe University of SydneySydneyAustralia Melanoma Institute AustraliaThe University of SydneySydneyAustralia
M. Drummond Cancer Epidemiology and Prevention ResearchSydney School of Public HealthThe University of SydneySydneyAustralia Melanoma Institute AustraliaThe University of SydneySydneyAustralia
D.T. Bishop Section of Epidemiology and BiostatisticsLeeds Institute of Cancer and PathologyUniversity of LeedsLeedsUK
L. Azizi School of Mathematics and StatisticsThe University of SydneySydneyAustralia
H. Schmid Centre for Cancer ResearchWestmead Institute for Medical ResearchThe University of SydneySydneyAustralia
M.A. Jenkins Centre for Epidemiology and BiostatisticsMelbourne School of Population and Global HealthThe University of MelbourneMelbourneAustralia
J.L. Hopper Centre for Epidemiology and BiostatisticsMelbourne School of Population and Global HealthThe University of MelbourneMelbourneAustralia
B.K. Armstrong Cancer Epidemiology and Prevention ResearchSydney School of Public HealthThe University of SydneySydneyAustralia
J.F. Aitken Viertel Centre for Research in Cancer ControlCancer Council QueenslandBrisbaneAustralia
R.F. Kefford Melanoma Institute AustraliaThe University of SydneySydneyAustralia Macquarie University Health Sciences CentreMacquarie UniversitySydneyAustralia
G.G. Giles Centre for Epidemiology and BiostatisticsMelbourne School of Population and Global HealthThe University of MelbourneMelbourneAustralia Cancer Epidemiology CentreCancer Council VictoriaMelbourneAustralia
F. Demenais Genetic Variation and Human Diseases UnitUMR‐946INSERMUniversité Paris DiderotUniversité Sorbonne Paris CitéParisFrance
A.M. Goldstein Human Genetics ProgramDivision of Cancer Epidemiology and GeneticsNational Cancer InstituteBethesdaMDUSA
J.H. Barrett Section of Epidemiology and BiostatisticsLeeds Institute of Cancer and PathologyUniversity of LeedsLeedsUK
P.A. Kanetsky Cancer Epidemiology ProgramMoffitt Cancer CenterTampaFLUSA
D.E. Elder Department of Pathology and Laboratory MedicineUniversity of PennsylvaniaPhiladelphiaPAUSA
G.J. Mann Melanoma Institute AustraliaThe University of SydneySydneyAustralia Centre for Cancer ResearchWestmead Institute for Medical ResearchThe University of SydneySydneyAustralia
J.A. Newton‐Bishop Section of Epidemiology and BiostatisticsLeeds Institute of Cancer and PathologyUniversity of LeedsLeedsUK

Collapse

Li WQ, Cho E, Weinstock MA, Li S, Stampfer MJ, Qureshi AA. Cutaneous nevi and risk of melanoma death in women and men: A prospective study. J Am Acad Dermatol 2019;80:1284-1291. [PMID: 30639880 PMCID: PMC6462416 DOI: 10.1016/j.jaad.2018.12.058] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 12/05/2018] [Accepted: 12/24/2018] [Indexed: 12/24/2022]

Affiliation(s)

Wen-Qing Li Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Beijing, China; Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.
Eunyoung Cho Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Martin A Weinstock Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island; Center for Dermatoepidemiology, VA Medical Center, Providence, Rhode Island
Suyun Li Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; School of Public Health, Institute for Chemical Carcinogenesis, Guangzhou Medical University, Guangzhou, China
Meir J Stampfer Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
Abrar A Qureshi Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Collapse

Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening. Eur J Cancer Prev 2019;27:563-569. [PMID: 28692584 DOI: 10.1097/cej.0000000000000392] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]

Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Green AC, Neale RE, Whiteman DC. Association between Phenotypic Characteristics and Melanoma in a Large Prospective Cohort Study. J Invest Dermatol 2019;139:665-672. [DOI: 10.1016/j.jid.2018.09.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Revised: 08/31/2018] [Accepted: 09/20/2018] [Indexed: 12/16/2022]

Smith DJM. The Melanocortin 1 receptor and its influence on naevi and melanoma in dark-skinned phenotypes. Australas J Dermatol 2018;60:192-199. [PMID: 30585306 DOI: 10.1111/ajd.12982] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 10/20/2018] [Indexed: 12/19/2022]

Cust AE, Mishra K, Berwick M. Melanoma - role of the environment and genetics. Photochem Photobiol Sci 2018;17:1853-1860. [PMID: 30113042 DOI: 10.1039/c7pp00411g] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]

Cust AE, Drummond M, Kanetsky PA, Goldstein AM, Barrett JH, MacGregor S, Law MH, Iles MM, Bui M, Hopper JL, Brossard M, Demenais F, Taylor JC, Hoggart C, Brown KM, Landi MT, Newton-Bishop JA, Mann GJ, Bishop DT. Assessing the Incremental Contribution of Common Genomic Variants to Melanoma Risk Prediction in Two Population-Based Studies. J Invest Dermatol 2018;138:2617-2624. [PMID: 29890168 PMCID: PMC6249137 DOI: 10.1016/j.jid.2018.05.023] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 05/29/2018] [Accepted: 05/30/2018] [Indexed: 01/02/2023]

Affiliation(s)

Anne E Cust Cancer Epidemiology and Prevention Research, Sydney School of Public Health, The University of Sydney, Sydney, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Martin Drummond Cancer Epidemiology and Prevention Research, Sydney School of Public Health, The University of Sydney, Sydney, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia
Peter A Kanetsky Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
Alisa M Goldstein Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
Jennifer H Barrett Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
Stuart MacGregor Statistical Genetics Lab, QIMR Berghofer Medical Research Institute, Brisbane, Australia
Matthew H Law Statistical Genetics Lab, QIMR Berghofer Medical Research Institute, Brisbane, Australia
Mark M Iles Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
Minh Bui Centre for Epidemiology and Biostatistics, Melbourne School of Population Health, University of Melbourne, Australia
John L Hopper Centre for Epidemiology and Biostatistics, Melbourne School of Population Health, University of Melbourne, Australia
Myriam Brossard INSERM, UMR 946, Genetic Variation and Human Diseases Unit, Paris, France; Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
Florence Demenais INSERM, UMR 946, Genetic Variation and Human Diseases Unit, Paris, France; Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
John C Taylor Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
Clive Hoggart Section of Paediatrics, Division of Infectious Diseases, Department of Medicine, Imperial College London, London, UK
Kevin M Brown Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
Maria Teresa Landi Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
Julia A Newton-Bishop Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
Graham J Mann Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia
D Timothy Bishop Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK

Collapse

Duffy DL, Zhu G, Li X, Sanna M, Iles MM, Jacobs LC, Evans DM, Yazar S, Beesley J, Law MH, Kraft P, Visconti A, Taylor JC, Liu F, Wright MJ, Henders AK, Bowdler L, Glass D, Ikram MA, Uitterlinden AG, Madden PA, Heath AC, Nelson EC, Green AC, Chanock S, Barrett JH, Brown MA, Hayward NK, MacGregor S, Sturm RA, Hewitt AW, Kayser M, Hunter DJ, Newton Bishop JA, Spector TD, Montgomery GW, Mackey DA, Smith GD, Nijsten TE, Bishop DT, Bataille V, Falchi M, Han J, Martin NG. Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways. Nat Commun 2018;9:4774. [PMID: 30429480 PMCID: PMC6235897 DOI: 10.1038/s41467-018-06649-5] [Citation(s) in RCA: 86] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Accepted: 09/13/2018] [Indexed: 11/09/2022] Open

Affiliation(s)

David L Duffy QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Gu Zhu QIMR Berghofer Medical Research Institute, Brisbane, Australia
Xin Li Department of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, 63110, USA
Marianna Sanna Department of Twin Research & Genetic Epidemiology, St Thomas Hospital Campus, Kings College, London, UK
Mark M Iles Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
Leonie C Jacobs Department of Dermatology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
David M Evans MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia
Seyhan Yazar Centre for Ophthalmology and Vision Science, University of Western Australia and the Lions Eye Institute, Perth, Australia
Jonathan Beesley QIMR Berghofer Medical Research Institute, Brisbane, Australia
Matthew H Law QIMR Berghofer Medical Research Institute, Brisbane, Australia
Peter Kraft Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, 02115, MA, USA
Alessia Visconti Department of Twin Research & Genetic Epidemiology, St Thomas Hospital Campus, Kings College, London, UK
John C Taylor Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
Fan Liu Department of Genetic Identification, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
Margaret J Wright QIMR Berghofer Medical Research Institute, Brisbane, Australia
Anjali K Henders QIMR Berghofer Medical Research Institute, Brisbane, Australia Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
Lisa Bowdler QIMR Berghofer Medical Research Institute, Brisbane, Australia
Dan Glass Department of Twin Research & Genetic Epidemiology, St Thomas Hospital Campus, Kings College, London, UK
M Arfan Ikram Department of Epidemiology, Erasmus MC, Rotterdam, Netherlands
André G Uitterlinden Department of Epidemiology, Erasmus MC, Rotterdam, Netherlands Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands
Pamela A Madden Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, 63110, USA
Andrew C Heath Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, 63110, USA
Elliot C Nelson Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, 63110, USA
Adele C Green QIMR Berghofer Medical Research Institute, Brisbane, Australia Molecular Oncology Group, CRUK Manchester Institute, University of Manchester, Manchester, UK
Stephen Chanock Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
Jennifer H Barrett Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
Matthew A Brown University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia
Nicholas K Hayward QIMR Berghofer Medical Research Institute, Brisbane, Australia
Stuart MacGregor QIMR Berghofer Medical Research Institute, Brisbane, Australia
Richard A Sturm Dermatology Research Centre, University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia
Alex W Hewitt Centre for Ophthalmology and Vision Science, University of Western Australia and the Lions Eye Institute, Perth, Australia
Manfred Kayser Department of Genetic Identification, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
David J Hunter Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, 02115, MA, USA
Julia A Newton Bishop Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
Timothy D Spector Department of Twin Research & Genetic Epidemiology, St Thomas Hospital Campus, Kings College, London, UK
Grant W Montgomery QIMR Berghofer Medical Research Institute, Brisbane, Australia Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
David A Mackey Centre for Ophthalmology and Vision Science, University of Western Australia and the Lions Eye Institute, Perth, Australia
George Davey Smith MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
Tamar E Nijsten Department of Dermatology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
D Timothy Bishop Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
Veronique Bataille Department of Twin Research & Genetic Epidemiology, St Thomas Hospital Campus, Kings College, London, UK
Mario Falchi Department of Twin Research & Genetic Epidemiology, St Thomas Hospital Campus, Kings College, London, UK
Jiali Han Department of Epidemiology, Richard M. Fairbanks School of Public Health, Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, 63110, USA
Nicholas G Martin QIMR Berghofer Medical Research Institute, Brisbane, Australia

Collapse

Behrens G, Niedermaier T, Berneburg M, Schmid D, Leitzmann MF. Physical activity, cardiorespiratory fitness and risk of cutaneous malignant melanoma: Systematic review and meta-analysis. PLoS One 2018;13:e0206087. [PMID: 30379884 PMCID: PMC6209223 DOI: 10.1371/journal.pone.0206087] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Accepted: 10/05/2018] [Indexed: 01/08/2023] Open

Foo S, Nightingale P, Gazzani P, Bader E, Ogboli M, Martin-Clavijo A, Milford D, Kelly D, Moss C, Thomson M. A 10-year longitudinal follow-up study of a U.K. paediatric transplant population to assess for skin cancer. Br J Dermatol 2018;179:1368-1375. [PMID: 29701240 DOI: 10.1111/bjd.16697] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/05/2018] [Indexed: 01/25/2023]

Bisevac JP, Djukic M, Stanojevic I, Stevanovic I, Mijuskovic Z, Djuric A, Gobeljic B, Banovic T, Vojvodic D. Association Between Oxidative Stress and Melanoma Progression. J Med Biochem 2018;37:12-20. [PMID: 30581337 PMCID: PMC6294103 DOI: 10.1515/jomb-2017-0040] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Accepted: 07/28/2017] [Indexed: 12/22/2022] Open

Pajares MÁ. PDRG1 at the interface between intermediary metabolism and oncogenesis. World J Biol Chem 2017;8:175-186. [PMID: 29225734 PMCID: PMC5714802 DOI: 10.4331/wjbc.v8.i4.175] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 11/14/2017] [Accepted: 11/19/2017] [Indexed: 02/05/2023] Open

Berg SA, Ming ME. Recent Advances in Our Understanding of the Epidemiology of Melanoma. CURRENT DERMATOLOGY REPORTS 2017. [DOI: 10.1007/s13671-017-0193-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]

Plasmeijer EI, Nguyen TMU, Olsen CM, Janda M, Soyer HP, Green AC. The Natural History of Common Melanocytic Nevi: A Systematic Review of Longitudinal Studies in the General Population. J Invest Dermatol 2017;137:2017-2018. [PMID: 28528913 DOI: 10.1016/j.jid.2017.03.040] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Revised: 03/23/2017] [Accepted: 03/28/2017] [Indexed: 11/17/2022]

Hübner J, Waldmann A, Geller AC, Weinstock MA, Eisemann N, Noftz M, Bertram S, Nolte S, Volkmer B, Greinert R, Breitbart E, Katalinic A. Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma. Br J Cancer 2017;116:253-259. [PMID: 27898656 PMCID: PMC5243984 DOI: 10.1038/bjc.2016.390] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Revised: 11/01/2016] [Accepted: 11/03/2016] [Indexed: 11/28/2022] Open

Affiliation(s)

J Hübner Institute for Social Medicine and Epidemiology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany
A Waldmann Institute for Social Medicine and Epidemiology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany
A C Geller Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
M A Weinstock Center for Dermatoepidemiology, VA Medical Center—111D, 830 Chalkstone Avenue, Providence, RI 02908, USA Department of Dermatology, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA Departments of Dermatology and Epidemiology, Brown University, 593 Eddy Street, Providence, RI 02903, USA
N Eisemann Institute for Social Medicine and Epidemiology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany
M Noftz Institute for Social Medicine and Epidemiology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany
S Bertram Institute for Social Medicine and Epidemiology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany
S Nolte Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Charité—Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany Population Health Strategic Research Centre, Deakin University, 221 Burwood Highway, Melbourne, VIC 3125, Australia
B Volkmer Division of Molecular Cell Biology, Dermatology Center, Elbe Clinics Stade-Buxtehude, Am Krankenhaus 1, Buxtehude 21614, Germany
R Greinert Division of Molecular Cell Biology, Dermatology Center, Elbe Clinics Stade-Buxtehude, Am Krankenhaus 1, Buxtehude 21614, Germany
E Breitbart Association of Dermatological Prevention e.V., Cremon 11, Hamburg 20457, Germany
A Katalinic Institute for Social Medicine and Epidemiology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany Cancer Registry of Schleswig-Holstein, Ratzeburger Allee 160, Lübeck 23562, Germany

Collapse

Belbasis L, Stefanaki I, Stratigos AJ, Evangelou E. Non-genetic risk factors for cutaneous melanoma and keratinocyte skin cancers: An umbrella review of meta-analyses. J Dermatol Sci 2016;84:330-339. [PMID: 27663092 DOI: 10.1016/j.jdermsci.2016.09.003] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 08/25/2016] [Accepted: 09/08/2016] [Indexed: 12/20/2022]

Abstract

BACKGROUND

Skin cancers have a complex disease mechanism, involving both genetic and non-genetic risk factors. Numerous meta-analyses have been published claiming statistically significant associations between non-genetic risk factors and skin cancers without applying a thorough methodological assessment.

OBJECTIVE

The present study maps the literature on the non-genetic risk factors of skin cancers, assesses the presence of statistical biases and identifies the associations with robust evidence.

METHODS

We searched PubMed up to January 20, 2016 to identify systematic reviews and meta-analyses of observational studies that examined associations between non-genetic factors and skin cancers. For each meta-analysis, we estimated the summary effect size by random-effects and fixed-effects models, the 95% confidence interval and the 95% prediction interval. We also assessed the between-study heterogeneity (I2 metric), evidence for small-study effects and excess significance bias.

RESULTS

Forty-four eligible papers were identified and included a total of 85 associations. Twenty-one associations were significant at P<10-6. Fifty-two associations had large or very large heterogeneity. Evidence for small-study effects and excess significance bias was found in fifteen and thirteen associations, respectively. Overall, thirteen associations (actinic keratosis, serum vitamin D, sunburns, and hair color for basal cell carcinoma and density of freckles, eye color, hair color, history of melanoma, skin type, sunburns, premalignant skin lesions, common and atypical nevi for melanoma) presented high level of credibility.

CONCLUSION

The majority of meta-analyses on non-genetic risk factors for skin cancers suffered from large between-study heterogeneity and small-study effects or excess significance bias. The associations with convincing and highly suggestive evidence were mainly focused on skin photosensitivity and phenotypic characteristics.

Collapse

Karimi K, Lindgren TH, Koch CA, Brodell RT. Obesity as a risk factor for malignant melanoma and non-melanoma skin cancer. Rev Endocr Metab Disord 2016;17:389-403. [PMID: 27832418 DOI: 10.1007/s11154-016-9393-9] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]

Fox C, Lambie D, Wilmott JS, Pinder A, Pavey S, Lê Cao KA, Akalin T, Karaarslan IK, Ozdemir F, Scolyer RA, Yamada M, Soyer HP, Schaider H, Gabrielli B. Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell Melanoma Res 2016;29:444-52. [PMID: 27166757 DOI: 10.1111/pcmr.12489] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Accepted: 05/04/2016] [Indexed: 11/27/2022]

Agarwal P, Nambiyar K, Manju Kaushal, Bhardwaj M. Primary Malignant Melanoma of Pleura: A Case Report and Literature Review. Diagn Cytopathol 2016;44:648-52. [PMID: 27164972 DOI: 10.1002/dc.23497] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Revised: 04/19/2016] [Accepted: 04/23/2016] [Indexed: 12/19/2022]

Recognizing melanoma: Diagnosis and treatment options. Nurse Pract 2016;41:24-9; quiz 29-30. [PMID: 26974049 DOI: 10.1097/01.npr.0000481508.24736.81] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Kamath S, Miller KA, Cockburn MG. Current Data on Risk Factor Estimates Does Not Explain the Difference in Rates of Melanoma between Hispanics and Non-Hispanic Whites. J Skin Cancer 2016;2016:2105250. [PMID: 27092276 PMCID: PMC4820624 DOI: 10.1155/2016/2105250] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2015] [Revised: 02/23/2016] [Accepted: 02/23/2016] [Indexed: 01/07/2023] Open

Robbins HA, Clarke CA, Arron ST, Tatalovich Z, Kahn AR, Hernandez BY, Paddock L, Yanik EL, Lynch CF, Kasiske BL, Snyder J, Engels EA. Melanoma Risk and Survival among Organ Transplant Recipients. J Invest Dermatol 2015;135:2657-2665. [PMID: 26270022 PMCID: PMC4640996 DOI: 10.1038/jid.2015.312] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Revised: 04/05/2015] [Accepted: 06/10/2015] [Indexed: 01/07/2023]

Segatto MM, Bonamigo RR, Hohmann CB, Müller KR, Bakos L, Mastroeni S, Fortes C. Residential and occupational exposure to pesticides may increase risk for cutaneous melanoma: a case-control study conducted in the south of Brazil. Int J Dermatol 2015;54:e527-38. [DOI: 10.1111/ijd.12826] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2014] [Revised: 07/07/2014] [Accepted: 07/22/2014] [Indexed: 01/22/2023]

Miller KA, Langholz BM, Zadnick J, Hamilton AS, Cozen W, Mack TM, Cockburn MG. Prevalence and predictors of recent skin examination in a population-based twin cohort. Cancer Epidemiol Biomarkers Prev 2015;24:1190-8. [PMID: 25994738 DOI: 10.1158/1055-9965.epi-14-1389] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2014] [Accepted: 04/27/2015] [Indexed: 11/16/2022] Open

Palmieri G, Colombino M, Casula M, Budroni M, Manca A, Sini MC, Lissia A, Stanganelli I, Ascierto PA, Cossu A. Epidemiological and genetic factors underlying melanoma development in Italy. Melanoma Manag 2015;2:149-163. [PMID: 30190844 PMCID: PMC6094587 DOI: 10.2217/mmt.15.12] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open

Wang Q, Chen J, Dassarath M, Yin Z, Yang X, Yang K, Wu G. Primary malignant melanoma of the pleura with rapid progression: A case report and literature review. Oncol Lett 2015;9:2713-2715. [PMID: 26137133 DOI: 10.3892/ol.2015.3104] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 02/17/2015] [Indexed: 02/05/2023] Open

Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part II. Screening, education, and future directions. J Am Acad Dermatol 2014;71:611.e1-611.e10; quiz 621-2. [PMID: 25219717 DOI: 10.1016/j.jaad.2014.05.045] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2014] [Revised: 05/15/2014] [Accepted: 05/21/2014] [Indexed: 11/22/2022]

Increased incidence of melanoma in situ in Denmark from 1997 to 2011. Melanoma Res 2014;24:488-95. [DOI: 10.1097/cmr.0000000000000092] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]

Abbott NCD, Pandeya N, Ong N, McClenahan P, Smithers BM, Green A, Soyer HP. Changeable naevi in people at high risk for melanoma. Australas J Dermatol 2014;56:14-8. [DOI: 10.1111/ajd.12181] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2014] [Accepted: 05/05/2014] [Indexed: 11/26/2022]